{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:53:48Z","timestamp":1793411628479,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"spanish society of medical oncology"},{"name":"spanish society of medical radiology"},{"DOI":"10.13039\/100006239","name":"society of nuclear medicine and molecular imaging","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006239","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone metastases are very common complications associated with certain types of cancers that frequently negatively impact the quality of life and functional status of patients; thus, early detection is necessary for the implementation of immediate therapeutic measures to reduce the risk of skeletal complications and improve survival and quality of life. There is no consensus or universal standard approach for the detection of bone metastases in cancer patients based on imaging. Endorsed by the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Medical Radiology (SERAM), and the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) a group of experts met to discuss and provide an up-to-date review of our current understanding of the biological mechanisms through which tumors spread to the bone and describe the imaging methods available to diagnose bone metastasis and monitor their response to oncological treatment, focusing on patients with breast and prostate cancer. According to current available data, the use of next-generation imaging techniques, including whole-body diffusion-weighted MRI, PET\/CT, and PET\/MRI with novel radiopharmaceuticals, is recommended instead of the classical combination of CT and bone scan in detection, staging and response assessment of bone metastases from prostate and breast cancer.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial registration:<\/jats:bold>\n                    Not applicable.\n                  <\/jats:p>","DOI":"10.1007\/s12094-022-02784-0","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T06:02:27Z","timestamp":1644732147000},"page":"1290-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"J.","family":"Orcajo-Rincon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mu\u00f1oz-Langa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Sep\u00falveda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C.","family":"Fern\u00e1ndez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Noriega-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sanz-Viedma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Vilanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-3396","authenticated-orcid":false,"given":"A.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"2784_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s\u20139s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931.","journal-title":"Clin Cancer Res"},{"key":"2784_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.24084","volume":"81","author":"A Amelot","year":"2021","unstructured":"Amelot A, Terrier LM, Le Nail LR, Cristini J, Cook AR, Buffenoir K, Pascal-Moussellard H, Carpentier A, Dubory A, Mathon B. Spine metastasis in patients with prostate cancer: survival prognosis assessment. Prostate. 2021;81:91\u2013101. https:\/\/doi.org\/10.1002\/pros.24084.","journal-title":"Prostate"},{"key":"2784_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277\u2013300. https:\/\/doi.org\/10.3322\/caac.20073.","journal-title":"CA Cancer J Clin"},{"key":"2784_CR4","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.4103\/2152-7806.182549","volume":"7","author":"JA Reddington","year":"2016","unstructured":"Reddington JA, Mendez GA, Ching A, Kubicky CD, Klimo P Jr, Ragel BT. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg Neurol Int. 2016;7:S361\u20135. https:\/\/doi.org\/10.4103\/2152-7806.182549.","journal-title":"Surg Neurol Int"},{"key":"2784_CR5","doi-asserted-by":"publisher","first-page":"5971615","DOI":"10.1155\/2019\/5971615","volume":"2019","author":"AT Kawai","year":"2019","unstructured":"Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarr\u00f3 M, Kaye JA. Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US. Prostate Cancer. 2019;2019:5971615. https:\/\/doi.org\/10.1155\/2019\/5971615.","journal-title":"Prostate Cancer"},{"key":"2784_CR6","doi-asserted-by":"publisher","first-page":"e0234927","DOI":"10.1371\/journal.pone.0234927","volume":"15","author":"S Hong","year":"2020","unstructured":"Hong S, Youk T, Lee SJ, Kim KM, Vajdic CM. Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study. PLoS ONE. 2020;15:e0234927. https:\/\/doi.org\/10.1371\/journal.pone.0234927.","journal-title":"PLoS ONE"},{"key":"2784_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364. https:\/\/doi.org\/10.1056\/NEJMra030831.","journal-title":"N Engl J Med"},{"key":"2784_CR8","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O\u2019Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32:3483\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.2561.","journal-title":"J Clin Oncol"},{"key":"2784_CR9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","volume":"81","author":"PF Schellhammer","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013;81:1297\u2013302. https:\/\/doi.org\/10.1016\/j.urology.2013.01.061.","journal-title":"Urology"},{"key":"2784_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med"},{"key":"2784_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.urology.2013.10.026","volume":"83","author":"ED Crawford","year":"2014","unstructured":"Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664\u20139. https:\/\/doi.org\/10.1016\/j.urology.2013.10.026.","journal-title":"Urology"},{"key":"2784_CR12","unstructured":"Mottet N, Van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvie`re O, Schoots IG, Tilki D, Wiegel T, Willemse P-PM, Cornford P. EAU-ESTRO-ESUR-SIOG 2019 guidelines on prostate cancer. 2019. https:\/\/uroweb.org\/guideline\/prostate-cancer\/#5. Accessed 12 Sept 2019."},{"key":"2784_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15\u201325. https:\/\/doi.org\/10.1038\/nrurol.2016.175.","journal-title":"Nat Rev Urol"},{"key":"2784_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","volume":"126","author":"M Trovo","year":"2018","unstructured":"Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177\u201380. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.032.","journal-title":"Radiother Oncol"},{"key":"2784_CR15","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/jco.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138. https:\/\/doi.org\/10.1200\/jco.20.00818.","journal-title":"J Clin Oncol"},{"key":"2784_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/SPC.0b013e3282f0c74f","volume":"1","author":"JB Lattouf","year":"2007","unstructured":"Lattouf JB, Saad F. Preservation of bone health in prostate cancer. Curr Opin Support Palliat Care. 2007;1:192\u20137. https:\/\/doi.org\/10.1097\/SPC.0b013e3282f0c74f.","journal-title":"Curr Opin Support Palliat Care"},{"key":"2784_CR17","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/s1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garc\u00eda-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312. https:\/\/doi.org\/10.1016\/s1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"key":"2784_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11547-018-0955-7","volume":"124","author":"G Petralia","year":"2019","unstructured":"Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, Grazioli L, Colagrande S, Giovagnoni A, Bellomi M. Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med. 2019;124:218\u201333. https:\/\/doi.org\/10.1007\/s11547-018-0955-7.","journal-title":"Radiol Med"},{"key":"2784_CR19","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed 23 Apr 2019."},{"key":"2784_CR20","unstructured":"Yu HM, Hoffe SE. Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults. UpToDate 2019. 2019. https:\/\/www.uptodate.com\/contents\/epidemiology-clinical-presentation-and-diagnosis-of-bone-metastasis-in-adults? Accessed 12 Sept 2019."},{"key":"2784_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","volume":"3","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Fanti S, Vargas HA, Petralia G, Schlemmer HP, Tombal B, de Bono J. Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus. 2017;3:223\u201339. https:\/\/doi.org\/10.1016\/j.euf.2016.06.018.","journal-title":"Eur Urol Focus"},{"key":"2784_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260804","author":"NM Bruckmann","year":"2021","unstructured":"Bruckmann NM, Kirchner J, Morawitz J, Umutlu L, Herrmann K, Bittner A-K, Hoffmann O, Mohrmann S, Ingenwerth M, Schaarschmidt BM, Li Y, Stang A, Antoch G, Sawicki LM, Buchbender C. Prospective comparison of CT and 18F-FDG PET\/MRI in N and M staging of primary breast cancer patients: initial results. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0260804.","journal-title":"PLoS ONE"},{"key":"2784_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/107327481201900204","volume":"19","author":"J Choi","year":"2012","unstructured":"Choi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control J Moffitt Cancer Cent. 2012;19:102\u201312. https:\/\/doi.org\/10.1177\/107327481201900204.","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"key":"2784_CR24","unstructured":"Yu HM, Hoffe SE. Overview of therapeutic approaches for adult patients with bone metastasis from solid tumors. UpToDate 2019. 2019. https:\/\/www.uptodate.com\/contents\/overview-of-therapeutic-approaches-for-adult-patients-with-bone-metastasis-from-solid-tumors? . Accessed 12 Sept 2019."},{"key":"2784_CR25","doi-asserted-by":"publisher","first-page":"116243","DOI":"10.1016\/j.bone.2021.116243","volume":"154","author":"R von Moos","year":"2022","unstructured":"von Moos R, Lewis K, Massey L, Marongiu A, Rider A, Seesaghur A. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe. Bone. 2022;154:116243. https:\/\/doi.org\/10.1016\/j.bone.2021.116243.","journal-title":"Bone"},{"key":"2784_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","volume":"7","author":"GJ O'Sullivan","year":"2015","unstructured":"O\u2019Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202\u201311. https:\/\/doi.org\/10.4329\/wjr.v7.i8.202.","journal-title":"World J Radiol"},{"key":"2784_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1148\/radiol.2019181931","volume":"292","author":"R Perez-Lopez","year":"2019","unstructured":"Perez-Lopez R, Tunariu N, Padhani AR, Oyen WJG, Fanti S, Vargas HA, Omlin A, Morris MJ, de Bono J, Koh DM. Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art. Radiology. 2019;292:273\u201386. https:\/\/doi.org\/10.1148\/radiol.2019181931.","journal-title":"Radiology"},{"key":"2784_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/bd-2007-26108","volume":"26","author":"AL Allan","year":"2006","unstructured":"Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006;26:87\u201398. https:\/\/doi.org\/10.3233\/bd-2007-26108.","journal-title":"Breast Dis"},{"issue":"Suppl 3","key":"2784_CR29","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","volume":"36","author":"D Santini","year":"2010","unstructured":"Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G. New molecular targets in bone metastases. Cancer Treat Rev. 2010;36(Suppl 3):S6-10. https:\/\/doi.org\/10.1016\/S0305-7372(10)70013-X.","journal-title":"Cancer Treat Rev"},{"key":"2784_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","volume":"48","author":"A Lipton","year":"2011","unstructured":"Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48:96\u20139. https:\/\/doi.org\/10.1016\/j.bone.2010.10.161.","journal-title":"Bone"},{"key":"2784_CR31","first-page":"1356","volume":"46","author":"E Even-Sapir","year":"2005","unstructured":"Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356\u201367.","journal-title":"J Nucl Med"},{"key":"2784_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/jmri.24548","volume":"39","author":"AR Padhani","year":"2014","unstructured":"Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014;39:1049\u201378. https:\/\/doi.org\/10.1002\/jmri.24548.","journal-title":"J Magn Reson Imaging"},{"key":"2784_CR33","first-page":"53","volume":"45","author":"LD Rybak","year":"2001","unstructured":"Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53\u201364.","journal-title":"Q J Nucl Med"},{"key":"2784_CR34","first-page":"158","volume":"18","author":"R Karnholz","year":"1991","unstructured":"Karnholz R, Sze G. Current imaging in spinal metastatic disease. Semin Oncol. 1991;18:158\u201369.","journal-title":"Semin Oncol"},{"key":"2784_CR35","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s00330-011-2221-4","volume":"21","author":"HL Yang","year":"2011","unstructured":"Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21:2604\u201317. https:\/\/doi.org\/10.1007\/s00330-011-2221-4.","journal-title":"Eur Radiol"},{"key":"2784_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/0284185114530105","volume":"56","author":"YH Lee","year":"2015","unstructured":"Lee YH, Kim S, Lim D, Suh JS, Song HT. Spectral parametric segmentation of contrast-enhanced dual-energy CT to detect bone metastasis: feasibility sensitivity study using whole-body bone scintigraphy. Acta Radiol. 2015;56:458\u201364. https:\/\/doi.org\/10.1177\/0284185114530105.","journal-title":"Acta Radiol"},{"key":"2784_CR37","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1007\/s00330-021-08041-2","volume":"31","author":"TW Buus","year":"2021","unstructured":"Buus TW, Rasmussen F, Nellemann HM, L\u00f8gager V, Jensen AB, Hauerslev KR, Christiansen P, Pedersen EM. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study. Eur Radiol. 2021;31:8838\u201349. https:\/\/doi.org\/10.1007\/s00330-021-08041-2.","journal-title":"Eur Radiol"},{"key":"2784_CR38","first-page":"371","volume":"68","author":"A Luna","year":"2015","unstructured":"Luna A, Vilanova JC, Alcala ML. Total body MRI in early detection of bone metastasis and its indication in comparison to bone scan and other imaging techniques. Arch Esp Urol. 2015;68:371\u201390.","journal-title":"Arch Esp Urol"},{"key":"2784_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.mric.2015.08.006","volume":"24","author":"JC Vilanova","year":"2016","unstructured":"Vilanova JC, Baleato-Gonzalez S, Romero MJ, Carrascoso-Arranz J, Luna A. Assessment of musculoskeletal malignancies with functional MR imaging. Magn Reson Imaging Clin N Am. 2016;24:239\u201359. https:\/\/doi.org\/10.1016\/j.mric.2015.08.006.","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"2784_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1055\/s-0039-1685540","volume":"23","author":"JC Vilanova","year":"2019","unstructured":"Vilanova JC, Garcia-Figueiras R, Luna A, Baleato-Gonzalez S, Tomas X, Narvaez JA. Update on whole-body MRI in musculoskeletal applications. Semin Musculoskelet Radiol. 2019;23:312\u201323. https:\/\/doi.org\/10.1055\/s-0039-1685540.","journal-title":"Semin Musculoskelet Radiol"},{"key":"2784_CR41","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.26355\/eurrev_202007_21879","volume":"24","author":"G Sun","year":"2020","unstructured":"Sun G, Zhang YX, Liu F, Tu N. Whole-body magnetic resonance imaging is superior to skeletal scintigraphy for the detection of bone metastatic tumors: a meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24:7240\u201352. https:\/\/doi.org\/10.26355\/eurrev_202007_21879.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2784_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","volume":"55","author":"I Jambor","year":"2016","unstructured":"Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppanen M. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016;55:59\u201367. https:\/\/doi.org\/10.3109\/0284186X.2015.1027411.","journal-title":"Acta Oncol"},{"key":"2784_CR43","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"G Shen","year":"2014","unstructured":"Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503\u201313. https:\/\/doi.org\/10.1007\/s00256-014-1903-9.","journal-title":"Skeletal Radiol"},{"key":"2784_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2214\/ajr.19.21656","volume":"214","author":"W Sun","year":"2020","unstructured":"Sun W, Li M, Gu Y, Sun Z, Qiu Z, Zhou Y. Diagnostic value of whole-body DWI with background body suppression plus calculation of apparent diffusion coefficient at 3 T versus (18)F-FDG PET\/CT for detection of bone metastases. AJR Am J Roentgenol. 2020;214:446\u201354. https:\/\/doi.org\/10.2214\/ajr.19.21656.","journal-title":"AJR Am J Roentgenol"},{"key":"2784_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jmri.22608","volume":"34","author":"LM Wu","year":"2011","unstructured":"Wu LM, Gu HY, Zheng J, Xu X, Lin LH, Deng X, Zhang W, Xu JR. Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging. 2011;34:128\u201335. https:\/\/doi.org\/10.1002\/jmri.22608.","journal-title":"J Magn Reson Imaging"},{"key":"2784_CR46","doi-asserted-by":"publisher","first-page":"W336","DOI":"10.2214\/AJR.17.17984","volume":"209","author":"M Morone","year":"2017","unstructured":"Morone M, Bali MA, Tunariu N, Messiou C, Blackledge M, Grazioli L, Koh DM. Whole-body MRI: current applications in oncology. AJR Am J Roentgenol. 2017;209:W336\u201349. https:\/\/doi.org\/10.2214\/AJR.17.17984.","journal-title":"AJR Am J Roentgenol"},{"key":"2784_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479\u2013505. https:\/\/doi.org\/10.6004\/jnccn.2019.0023.","journal-title":"J Natl Compr Canc Netw"},{"key":"2784_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JP, Vande Berg B, Omoumi P, Tombal B. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol. 2012;62:68\u201375. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.020.","journal-title":"Eur Urol"},{"key":"2784_CR49","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/annonc\/mdu558","volume":"26","author":"DK Woolf","year":"2015","unstructured":"Woolf DK, Padhani AR, Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol. 2015;26:1048\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdu558.","journal-title":"Ann Oncol"},{"key":"2784_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1053\/j.semnuclmed.2009.07.003","volume":"39","author":"G Gnanasegaran","year":"2009","unstructured":"Gnanasegaran G, Cook G, Adamson K, Fogelman I. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT\/CT. Semin Nucl Med. 2009;39:380\u201395. https:\/\/doi.org\/10.1053\/j.semnuclmed.2009.07.003.","journal-title":"Semin Nucl Med"},{"key":"2784_CR51","doi-asserted-by":"publisher","first-page":"957364","DOI":"10.1155\/2012\/957364","volume":"2012","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhao C, Liu H, Hou H, Zhang H. Multiple metastasis-like bone lesions in scintigraphic imaging. J Biomed Biotechnol. 2012;2012:957364. https:\/\/doi.org\/10.1155\/2012\/957364.","journal-title":"J Biomed Biotechnol"},{"key":"2784_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1874471011306010007","volume":"6","author":"V Cuccurullo","year":"2013","unstructured":"Cuccurullo V, Cascini GL, Tamburrini O, Rotondo A, Mansi L. Bone metastases radiopharmaceuticals: an overview. Curr Radiopharm. 2013;6:41\u20137. https:\/\/doi.org\/10.2174\/1874471011306010007.","journal-title":"Curr Radiopharm"},{"key":"2784_CR53","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.crad.2016.01.026","volume":"71","author":"GK Azad","year":"2016","unstructured":"Azad GK, Cook GJ. Multi-technique imaging of bone metastases: spotlight on PET-CT. Clin Radiol. 2016;71:620\u201331. https:\/\/doi.org\/10.1016\/j.crad.2016.01.026.","journal-title":"Clin Radiol"},{"key":"2784_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1102\/1470-7330.2010.0022","volume":"10","author":"GJR Cook","year":"2010","unstructured":"Cook GJR. PET and PET\/CT imaging of skeletal metastases. Cancer Imaging. 2010;10:1\u20138. https:\/\/doi.org\/10.1102\/1470-7330.2010.0022.","journal-title":"Cancer Imaging"},{"key":"2784_CR55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3322\/canjclin.57.4.206","volume":"57","author":"DA Torigian","year":"2007","unstructured":"Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin. 2007;57:206\u201324. https:\/\/doi.org\/10.3322\/canjclin.57.4.206.","journal-title":"CA Cancer J Clin"},{"key":"2784_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/MNM.0b013e328364918a","volume":"34","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ. A literature review of 18F-fluoride PET\/CT and 18F-choline or 11C-choline PET\/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013;34:935\u201345. https:\/\/doi.org\/10.1097\/MNM.0b013e328364918a.","journal-title":"Nucl Med Commun"},{"key":"2784_CR57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11307-009-0239-7","volume":"12","author":"M Beheshti","year":"2010","unstructured":"Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12:98\u2013107. https:\/\/doi.org\/10.1007\/s11307-009-0239-7.","journal-title":"Mol Imaging Biol"},{"key":"2784_CR58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.remn.2017.07.004","volume":"37","author":"JRG Garzon","year":"2018","unstructured":"Garzon JRG, de Arcocha TM, Delgado-Bolton R, Ceci F, Ruiz SA, Rincon JO, Aroztegui APC, Velloso MJG, Vicente AMG. (68)Ga-PSMA PET\/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol. 2018;37:130\u20138. https:\/\/doi.org\/10.1016\/j.remn.2017.07.004.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"2784_CR59","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"2784_CR60","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261886","author":"JJ Cerci","year":"2021","unstructured":"Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, Novruzov F, Lengana T, Granados C, Kumar R, Rangarajan V, Al-Ibraheem A, Hourani M, Ali NS, Ahmad A, Keidar Z, Kucuk O, Elboga U, Bogoni M, Paez D. Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study). J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.261886.","journal-title":"J Nucl Med"},{"key":"2784_CR61","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114\u201321. https:\/\/doi.org\/10.1007\/s00259-016-3435-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2784_CR62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1470-2045(09)70088-9","volume":"10","author":"CM Costelloe","year":"2009","unstructured":"Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(09)70088-9.","journal-title":"Lancet Oncol"},{"key":"2784_CR63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/107327481201900202","volume":"19","author":"HHM Yu","year":"2012","unstructured":"Yu HHM, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control J Moffitt Cancer Cent. 2012;19:84\u201391. https:\/\/doi.org\/10.1177\/107327481201900202.","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"key":"2784_CR64","doi-asserted-by":"publisher","first-page":"e000037","DOI":"10.1136\/esmoopen-2016-000037","volume":"1","author":"H Shibata","year":"2016","unstructured":"Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016;1:e000037. https:\/\/doi.org\/10.1136\/esmoopen-2016-000037.","journal-title":"ESMO Open"},{"key":"2784_CR65","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s12094-015-1427-3","volume":"17","author":"JA Garcia-Saenz","year":"2015","unstructured":"Garcia-Saenz JA, Bermejo B, Estevez LG, Palomo AG, Gonzalez-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez CA, Ciruelos E. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015;17:939\u201345. https:\/\/doi.org\/10.1007\/s12094-015-1427-3.","journal-title":"Clin Transl Oncol"},{"key":"2784_CR66","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s12094-015-1476-7","volume":"17","author":"J Gavila","year":"2015","unstructured":"Gavila J, Lopez-Tarruella S, Saura C, Munoz M, Oliveira M, De la Cruz-Merino L, Morales S, Alvarez I, Virizuela JA, Martin M. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol. 2015;17:946\u201355. https:\/\/doi.org\/10.1007\/s12094-015-1476-7.","journal-title":"Clin Transl Oncol"},{"key":"2784_CR67","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1674. https:\/\/doi.org\/10.1093\/annonc\/mdz189.","journal-title":"Ann Oncol"},{"key":"2784_CR68","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortes J, Curigliano G, Dieras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger. Ann Oncol. 2018;29:1634\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdy192.","journal-title":"Ann Oncol"},{"key":"2784_CR69","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.urology.2009.12.050","volume":"76","author":"N Rajarubendra","year":"2010","unstructured":"Rajarubendra N, Bolton D, Lawrentschuk N. Diagnosis of bone metastases in urological malignancies\u2014an update. Urology. 2010;76:782\u201390. https:\/\/doi.org\/10.1016\/j.urology.2009.12.050.","journal-title":"Urology"},{"key":"2784_CR70","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cam4.119","volume":"2","author":"GA Ulaner","year":"2013","unstructured":"Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2:725\u201333. https:\/\/doi.org\/10.1002\/cam4.119.","journal-title":"Cancer Med"},{"key":"2784_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12094-018-02010-w","volume":"21","author":"JI Chacon Lopez-Muniz","year":"2019","unstructured":"Chacon Lopez-Muniz JI, de la Cruz ML, Gavila Gregori J, Martinez Duenas E, Oliveira M, Segui Palmer MA, Alvarez Lopez I, Antolin Novoa S, Bellet Ezquerra M, Lopez-Tarruella CS. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019;21:31\u201345. https:\/\/doi.org\/10.1007\/s12094-018-02010-w.","journal-title":"Clin Transl Oncol"},{"key":"2784_CR72","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cort\u00e9s J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol"},{"key":"2784_CR73","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"2784_CR74","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.bjc.6605546","volume":"102","author":"T Hamaoka","year":"2010","unstructured":"Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102:651\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6605546.","journal-title":"Br J Cancer"},{"key":"2784_CR75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12149-012-0595-2","volume":"26","author":"T Katayama","year":"2012","unstructured":"Katayama T, Kubota K, Machida Y, Toriihara A, Shibuya H. Evaluation of sequential FDG-PET\/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Ann Nucl Med. 2012;26:426\u201335. https:\/\/doi.org\/10.1007\/s12149-012-0595-2.","journal-title":"Ann Nucl Med"},{"key":"2784_CR76","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ejrad.2015.01.007","volume":"84","author":"Y Dong","year":"2015","unstructured":"Dong Y, Zheng S, Machida H, Wang B, Liu A, Liu Y, Zhang X. Differential diagnosis of osteoblastic metastases from bone islands in patients with lung cancer by single-source dual-energy CT: advantages of spectral CT imaging. Eur J Radiol. 2015;84:901\u20137. https:\/\/doi.org\/10.1016\/j.ejrad.2015.01.007.","journal-title":"Eur J Radiol"},{"key":"2784_CR77","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/rli.0000000000000343","volume":"52","author":"M Horger","year":"2017","unstructured":"Horger M, Thaiss WM, Wiesinger B, Ditt H, Fritz J, Nikolaou K, Kloth C. Longitudinal computed tomography monitoring of pelvic bones in patients with breast cancer using automated bone subtraction software. Investig Radiol. 2017;52:288\u201394. https:\/\/doi.org\/10.1097\/rli.0000000000000343.","journal-title":"Investig Radiol"},{"key":"2784_CR78","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1007\/s00330-013-2792-3","volume":"23","author":"FE Lecouvet","year":"2013","unstructured":"Lecouvet FE, Larbi A, Pasoglou V, Omoumi P, Tombal B, Michoux N, Malghem J, Lhommel R, Vande Berg BC. MRI for response assessment in metastatic bone disease. Eur Radiol. 2013;23:1986\u201397. https:\/\/doi.org\/10.1007\/s00330-013-2792-3.","journal-title":"Eur Radiol"},{"key":"2784_CR79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1148\/radiol.2017161965","volume":"284","author":"JM Winfield","year":"2017","unstructured":"Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR. Extracranial soft-tissue tumors: repeatability of apparent diffusion coefficient estimates from diffusion-weighted MR imaging. Radiology. 2017;284:88\u201399. https:\/\/doi.org\/10.1148\/radiol.2017161965.","journal-title":"Radiology"},{"key":"2784_CR80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","volume":"22","author":"NU Lin","year":"2013","unstructured":"Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22:203\u201310. https:\/\/doi.org\/10.1016\/j.breast.2013.03.006.","journal-title":"Breast"},{"key":"2784_CR81","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0009-9260(98)80168-2","volume":"53","author":"AL Brown","year":"1998","unstructured":"Brown AL, Middleton G, MacVicar AD, Husband JE. T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol. 1998;53:493\u2013501. https:\/\/doi.org\/10.1016\/s0009-9260(98)80168-2.","journal-title":"Clin Radiol"},{"key":"2784_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2017.03.001","volume":"77","author":"M Kosmin","year":"2017","unstructured":"Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer. 2017;77:109\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.001.","journal-title":"Eur J Cancer"},{"key":"2784_CR83","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1148\/radiol.2020192683","volume":"297","author":"M Kosmin","year":"2020","unstructured":"Kosmin M, Padhani AR, Gogbashian A, Woolf D, Ah-See ML, Ostler P, Sutherland S, Miles D, Noble J, Koh DM, Marshall A, Dunn J, Makris A. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology. 2020;297:622\u20139. https:\/\/doi.org\/10.1148\/radiol.2020192683.","journal-title":"Radiology"},{"key":"2784_CR84","unstructured":"National Institute for Health and Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment Clinical guideline. 2009. https:\/\/www.nice.org.uk\/guidance\/cg81\/resources\/advanced-breast-cancer-diagnosis-and-treatment-pdf-975683850181. Accessed 16 Aug 2017."},{"key":"2784_CR85","first-page":"14N","volume":"58","author":"KJ Donohoe","year":"2017","unstructured":"Donohoe KJ, Cohen EJ, Giammarile F, Grady E, Greenspan BS, Henkin RE, Millstine J, Smith GT, Srinivas S, Kauffman J, Ahuja S. Appropriate use criteria for bone scintigraphy in prostate and breast cancer: summary and excerpts. J Nucl Med. 2017;58:14N-17N.","journal-title":"J Nucl Med"},{"key":"2784_CR86","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Breast cancer version 1. 2018. http:\/\/www.NCCN.org."},{"key":"2784_CR87","first-page":"499","volume":"11","author":"L Chavdarova","year":"2006","unstructured":"Chavdarova L, Piperkova E, Tsonevska A, Timcheva K, Dimitrova M. Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer. J BUON. 2006;11:499\u2013504.","journal-title":"J BUON"},{"key":"2784_CR88","doi-asserted-by":"publisher","first-page":"e3753","DOI":"10.1097\/MD.0000000000003753","volume":"95","author":"KM Al-Muqbel","year":"2016","unstructured":"Al-Muqbel KM, Yaghan RJ. Effectiveness of 18F-FDG-PET\/CT vs bone scintigraphy in treatment response assessment of bone metastases in breast cancer. Medicine. 2016;95:e3753. https:\/\/doi.org\/10.1097\/MD.0000000000003753.","journal-title":"Medicine"},{"key":"2784_CR89","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.112.114298","volume":"54","author":"KK Wong","year":"2013","unstructured":"Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med. 2013;54:590\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.114298.","journal-title":"J Nucl Med"},{"key":"2784_CR90","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942\u201353. https:\/\/doi.org\/10.1200\/JCO.2004.08.181.","journal-title":"J Clin Oncol"},{"key":"2784_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jbo.2015.08.002","volume":"4","author":"M Araz","year":"2015","unstructured":"Araz M, Aras G, Kucuk ON. The role of 18F-NaF PET\/CT in metastatic bone disease. J Bone Oncol. 2015;4:92\u20137. https:\/\/doi.org\/10.1016\/j.jbo.2015.08.002.","journal-title":"J Bone Oncol"},{"key":"2784_CR92","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.remn.2015.08.001","volume":"35","author":"AMG Vicente","year":"2016","unstructured":"Vicente AMG, Castrej\u00f3n AS, Amo-Salas M, Fidalgo JFL, Sanchez MMM, Cabellos RA, Aunion RE, Madero VM. Glycolytic activity in breast cancer using 18F-FDG PET\/CT as prognostic predictor: a molecular phenotype approach. Rev Esp Med Nucl Imagen Mol. 2016;35:152\u20138. https:\/\/doi.org\/10.1016\/j.remn.2015.08.001.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"2784_CR93","doi-asserted-by":"publisher","first-page":"101042831772828","DOI":"10.1177\/1010428317728285","volume":"39","author":"AP Caresia Aroztegui","year":"2017","unstructured":"Caresia Aroztegui AP, Garc\u00eda Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, de Arcocha TM, Garcia-Velloso MJ. 18F-FDG PET\/CT in breast cancer: evidence-based recommendations in initial staging. Tumor Biol. 2017;39:1010428317728285. https:\/\/doi.org\/10.1177\/1010428317728285.","journal-title":"Tumor Biol"},{"key":"2784_CR94","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","volume":"1","author":"CM Costelloe","year":"2010","unstructured":"Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80\u201392. https:\/\/doi.org\/10.7150\/jca.1.80.","journal-title":"J Cancer"},{"issue":"Suppl 1","key":"2784_CR95","doi-asserted-by":"publisher","first-page":"34S","DOI":"10.2967\/jnumed.115.157875","volume":"57","author":"S Avril","year":"2016","unstructured":"Avril S, Muzic RF Jr, Plecha D, Traughber BJ, Vinayak S, Avril N. 18F-FDG PET\/CT for monitoring of treatment response in breast cancer. J Nucl Med. 2016;57(Suppl 1):34S-39S. https:\/\/doi.org\/10.2967\/jnumed.115.157875.","journal-title":"J Nucl Med"},{"key":"2784_CR96","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1200\/JCO.2001.19.11.2797","volume":"19","author":"JE Mortimer","year":"2001","unstructured":"Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797\u2013803. https:\/\/doi.org\/10.1200\/JCO.2001.19.11.2797.","journal-title":"J Clin Oncol"},{"key":"2784_CR97","doi-asserted-by":"publisher","first-page":"58105","DOI":"10.18632\/oncotarget.11171","volume":"7","author":"JH Kim","year":"2016","unstructured":"Kim JH. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review. Oncotarget. 2016;7:58105\u201310. https:\/\/doi.org\/10.18632\/oncotarget.11171.","journal-title":"Oncotarget"},{"key":"2784_CR98","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773\u201382. https:\/\/doi.org\/10.1016\/s0959-8049(99)00229-4.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2784_CR99","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"2784_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27\u201333. https:\/\/doi.org\/10.2967\/jnumed.115.162024.","journal-title":"J Nucl Med"},{"key":"2784_CR101","doi-asserted-by":"publisher","first-page":"153601211774538","DOI":"10.1177\/1536012117745386","volume":"17","author":"AVF Massicano","year":"2018","unstructured":"Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in nuclear medicine for imaging and therapy. Mol Imaging. 2018;17:1536012117745386. https:\/\/doi.org\/10.1177\/1536012117745386.","journal-title":"Mol Imaging"},{"key":"2784_CR102","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/01.ju.0000030900.55714.76","volume":"168","author":"J Rigaud","year":"2002","unstructured":"Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168:1423\u20136. https:\/\/doi.org\/10.1097\/01.ju.0000030900.55714.76.","journal-title":"J Urol"},{"key":"2784_CR103","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947.","journal-title":"Annu Rev Med"},{"key":"2784_CR104","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2016.76","volume":"13","author":"DE Spratt","year":"2016","unstructured":"Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. 2016;13:597\u2013610. https:\/\/doi.org\/10.1038\/nrclinonc.2016.76.","journal-title":"Nat Rev Clin Oncol"},{"key":"2784_CR105","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","volume":"19","author":"FE Lecouvet","year":"2018","unstructured":"Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018;19:e534\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(18)30571-0.","journal-title":"Lancet Oncol"},{"key":"2784_CR106","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71:81\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.033.","journal-title":"Eur Urol"},{"key":"2784_CR107","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.clgc.2019.12.010","volume":"18","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, Takahara T, Ishii C, Arita Y, Waseda Y, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. METastasis reporting and data system for prostate cancer as a prognostic imaging marker in castration-resistant prostate cancer. Clin Genitourin Cancer. 2020;18:e391\u20136. https:\/\/doi.org\/10.1016\/j.clgc.2019.12.010.","journal-title":"Clin Genitourin Cancer"},{"key":"2784_CR108","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2016160646","volume":"283","author":"R Perez-Lopez","year":"2017","unstructured":"Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology. 2017;283:168\u201377. https:\/\/doi.org\/10.1148\/radiol.2016160646.","journal-title":"Radiology"},{"key":"2784_CR109","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"2784_CR110","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","volume":"46","author":"H Jadvar","year":"2016","unstructured":"Jadvar H. Is there use for FDG-PET in prostate cancer? Semin Nucl Med. 2016;46:502\u20136. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.004.","journal-title":"Semin Nucl Med"},{"key":"2784_CR111","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","volume":"38","author":"L Evangelista","year":"2013","unstructured":"Evangelista L, Zattoni F, Guttilla A, Saladini G, Colletti PM, Rubello D. Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305\u201314. https:\/\/doi.org\/10.1097\/RLU.0b013e3182867f3c.","journal-title":"Clin Nucl Med"},{"key":"2784_CR112","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12149-019-01387-0","volume":"33","author":"C Schmidkonz","year":"2019","unstructured":"Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, B\u00e4uerle T. 68Ga-PSMA-11 PET\/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33:766\u201375. https:\/\/doi.org\/10.1007\/s12149-019-01387-0.","journal-title":"Ann Nucl Med"},{"key":"2784_CR113","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11547-018-0935-y","volume":"124","author":"L Filograna","year":"2019","unstructured":"Filograna L, Lenkowicz J, Cellini F, Dinapoli N, Manfrida S, Magarelli N, Leone A, Colosimo C, Valentini V. Identification of the most significant magnetic resonance imaging (MRI) radiomic features in oncological patients with vertebral bone marrow metastatic disease: a feasibility study. Radiol Med. 2019;124:50\u20137. https:\/\/doi.org\/10.1007\/s11547-018-0935-y.","journal-title":"Radiol Med"},{"key":"2784_CR114","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mri.2019.03.007","volume":"60","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yu B, Zhong F, Guo Q, Li K, Hou Y, Lin N. MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer. Magn Reson Imaging. 2019;60:76\u201384. https:\/\/doi.org\/10.1016\/j.mri.2019.03.007.","journal-title":"Magn Reson Imaging"},{"key":"2784_CR115","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.remn.2016.06.001","volume":"35","author":"C Riola-Parada","year":"2016","unstructured":"Riola-Parada C, Garc\u00eda-Ca\u00f1amaque L, P\u00e9rez-Due\u00f1as V, Garcerant-Tafur M, Carreras-Delgado JL. PET\/RM simult\u00e1nea vs. PET\/TC en oncolog\u00eda. Una revisi\u00f3n sistem\u00e1tica. Rev Esp Med Nucl Imagen Mol. 2016;35:306\u201312. https:\/\/doi.org\/10.1016\/j.remn.2016.06.001.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"2784_CR116","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/bjc.2015.112","volume":"112","author":"OA Catalano","year":"2015","unstructured":"Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, Guimaraes A, Vangel MG, Mahmood U, Soricelli A, Salvatore M. Comparison of CE-FDG-PET\/CT with CE-FDG-PET\/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer. 2015;112:1452\u201360. https:\/\/doi.org\/10.1038\/bjc.2015.112.","journal-title":"Br J Cancer"},{"key":"2784_CR117","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00330-018-5720-8","volume":"29","author":"D Botsikas","year":"2019","unstructured":"Botsikas D, Bagetakos I, Picarra M, Da Afonso Barisits Barisits AC, Boudabbous S, Montet X, Lam GT, Mainta I, Kalovidouri A, Becker M. What is the diagnostic performance of 18-FDG-PET\/MR compared to PET\/CT for the N- and M- staging of breast cancer? Eur Radiol. 2019;29:1787\u201398. https:\/\/doi.org\/10.1007\/s00330-018-5720-8.","journal-title":"Eur Radiol"},{"key":"2784_CR118","doi-asserted-by":"publisher","first-page":"108975","DOI":"10.1016\/j.ejrad.2020.108975","volume":"128","author":"J Kirchner","year":"2020","unstructured":"Kirchner J, Martin O, Umutlu L, Herrmann K, Bittner AK, Hoffmann O, Mohrmann S, Gauler T, Theurer S, Antke C, Esposito I, Kinner S, Schaarschmidt BM, Kowall B, L\u00fctke-Brintrup D, Stang A, Becker AS, Antoch G, Buchbender C. Impact of (18)F-FDG PET\/MR on therapeutic management in high risk primary breast cancer patients\u2014a prospective evaluation of staging algorithms. Eur J Radiol. 2020;128:108975. https:\/\/doi.org\/10.1016\/j.ejrad.2020.108975.","journal-title":"Eur J Radiol"},{"key":"2784_CR119","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12149-014-0825-x","volume":"28","author":"A Wetter","year":"2014","unstructured":"Wetter A, Lipponer C, Nensa F, Heusch P, R\u00fcbben H, Schlosser TW, P\u00f6ppel TD, Lauenstein TC, Nagarajah J. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET\/MRI: combined SUV and ADC analysis. Ann Nucl Med. 2014;28:405\u201310. https:\/\/doi.org\/10.1007\/s12149-014-0825-x.","journal-title":"Ann Nucl Med"},{"key":"2784_CR120","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11307-019-01392-9","volume":"22","author":"I Sonni","year":"2020","unstructured":"Sonni I, Minamimoto R, Baratto L, Gambhir SS, Loening AM, Vasanawala SS, Iagaru A. Simultaneous PET\/MRI in the evaluation of breast and prostate cancer using combined Na[(18)F] F and [(18)F]FDG: a focus on skeletal lesions. Mol Imaging Biol. 2020;22:397\u2013406. https:\/\/doi.org\/10.1007\/s11307-019-01392-9.","journal-title":"Mol Imaging Biol"},{"key":"2784_CR121","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00259-017-3850-x","volume":"45","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Nagel H, Becker AS, M\u00fcller J, Huellner M, Stolzmann P, Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA. Clinical performance of 68Ga-PSMA-11 PET\/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2018;45:20\u201330. https:\/\/doi.org\/10.1007\/s00259-017-3850-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2784_CR122","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00330-019-06353-y","volume":"30","author":"L Domachevsky","year":"2020","unstructured":"Domachevsky L, Bernstine H, Goldberg N, Nidam M, Catalano OA, Groshar D. Comparison between pelvic PSMA-PET\/MR and whole-body PSMA-PET\/CT for the initial evaluation of prostate cancer: a proof of concept study. Eur Radiol. 2020;30:328\u201336. https:\/\/doi.org\/10.1007\/s00330-019-06353-y.","journal-title":"Eur Radiol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T12:31:27Z","timestamp":1655123487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02784-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,13]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JMS-S is member of the advisory board for MSD and Abbvie and has received research grants to institution from Pfizer and has received travel grants from Ipsen. AL has received lecturer honorarium from Philips Healthcare and Canon. JOR, MM, JM-L, GF-P, EN, SS-V and JCV report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent\/ethical approval is not required for this type of project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}